Drug intelligence / Profile preview

DIOS-001

Development stage: Preclinical
Lead developer: Dioseve
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

DIOS-001 is an investigational cell therapy being developed by Dioseve for the treatment of female infertility. It utilizes induced pluripotent stem (iPS) cell-based technology to generate oocytes (eggs) *in vitro* without the need for fetal ovarian tissue. This approach aims to provide a potentially unlimited source of eggs to address infertility caused by poor egg quality or low ovarian reserve. The technology, which involves the differentiation of iPS cells into functional germ cells, has been published in the journal *Nature* and is protected by exclusive patents.

Beyond the preview

Go deeper on DIOS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIOS-001.

Explore the full profile